Neurocrine Biosciences | NBIX - 销售和管理费用



金融业
股票价格
USD
资产
USD 4.91B
现金及等价物
USD 266.5M
销售成本
USD 13.8M
流动资产
USD 2.44B
流动负债
USD 831.7M
债务
USD 406.2M
EBIT
USD 214.6M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 1.94
股本和储备
USD 3.41B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 17.34B
净收入
USD 197.9M
营业费用
USD 599.9M
营业利润
USD 214.6M
普通股股本
USD 100.6M
PE价格收益
28.09
税前利润
USD 246.8M
销售收入
USD 811M
销售和管理费用
USD 318.5M
股票
USD 64.5M
贸易债权人
USD 691.3M
应收帐款人
USD 768.1M


销售和管理费用 更改 日
AbbVie USD 3.58B 316M 2026-03
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Exelixis USD 139.6M 16.58M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Prothena USD 12.67M 5.02M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Repligen USD 76.54M 2.17M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xoma USD 11M 2.54M 2024-06